A recent study has shown that LIF regulates CD8+ T cell tumor infiltration by repressing CXCL9 expression in tumor-associated macrophages, and blocking LIF enhances T cell infiltration, improving responses to anti-PD1 therapy in glioblastoma and ovarian cancer models [20]. This evidence concerns the gene LIF and ovarian carcinoma.